JBIO
Jade Biosciences, Inc.
$12.82
0.34
(2.72%)
| Exchange: | |
| Market Cap: | 418.263M |
| Shares Outstanding: | 697439 |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Biotechnology | |||||
| CEO: | Tom Frohlich | |||||
| Full Time Employees: | 50 | |||||
| Address: |
|
|||||
| Website: | https://jadebiosciences.com |
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company’s pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
Click to read more…
Revenue Segmentation
EPS
Earnings Call
Income Statement
(* All numbers are in thousands)
Balance Sheet
(* All numbers are in thousands)
Cash Flow Statement
(* All numbers are in thousands)
Analyst Estimates
(* All numbers are in thousands)
